Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLNO Soleno Therapeutics

Market Closed 05-03 16:00:00 EDT

45.12

-4.11

-8.35%

盘后45.12

+0.000.00%

18:37 EDT

High48.49	Low44.98	Vol1.60M
Open47.14	D1 Closing49.23	Amplitude7.13%
Mkt Cap1.51B	Tradable Cap611.40M	Total Shares33.41M
T/O74.61M	T/O Rate11.80%	Tradable Shares13.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SLNO","market":"US","secType":"STK","nameCN":"Soleno Therapeutics","latestPrice":45.12,"timestamp":1714766400000,"preClose":49.23,"halted":0,"volume":1599401,"hourTrading":{"tag":"盘后","latestPrice":45.12,"preClose":45.12,"latestTime":"18:37 EDT","volume":7673,"amount":346264.543,"timestamp":1714775848072},"delay":0,"floatShares":13550569,"shares":33411329,"eps":-2.364036,"marketStatus":"Market Closed","change":-4.11,"latestTime":"05-03 16:00:00 EDT","open":47.14,"high":48.49,"low":44.98,"amount":74608318.84986301,"amplitude":0.071298,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.364036,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1714982400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":49.23,"preHourTrading":{"tag":"盘前","latestPrice":47.1497,"preClose":49.23,"latestTime":"09:29 EDT","volume":11139,"amount":523821.5001,"timestamp":1714742986329},"postHourTrading":{"tag":"盘后","latestPrice":45.12,"preClose":45.12,"latestTime":"18:37 EDT","volume":7673,"amount":346264.543,"timestamp":1714775848072},"volumeRatio":1.5358160647757912},"requestUrl":"/m/hq/s/SLNO","defaultTab":"news","newsList":[{"id":"2432134927","title":"Soleno Therapeutics Inc    expected to post a loss of 37 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2432134927","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432134927?lang=en_us&edition=fundamental","pubTime":"2024-05-03 19:02","pubTimestamp":1714734138,"startTime":"0","endTime":"0","summary":"* Soleno Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2024   *    * LSEG's mean analyst estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432470994","title":"BRIEF-Soleno Therapeutics Announces Pricing Of Approximately $138 Million Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2432470994","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432470994?lang=en_us&edition=fundamental","pubTime":"2024-05-03 10:34","pubTimestamp":1714703648,"startTime":"0","endTime":"0","summary":"May 2  - Soleno Therapeutics Inc   :   * SOLENO THERAPEUTICS ANNOUNCES PRICING OF APPROXIMATELY $138 MILLION PUBLIC OFFERING OF COMMON STOCK   * SOLENO THERAPEUTICS INC - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $46.00 PER SHARESource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432953245","title":"Soleno Therapeutics announces proposed common stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2432953245","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432953245?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:07","pubTimestamp":1714680473,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics  intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering.  Source: Press Release","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099080-soleno-therapeutics-announces-proposed-common-stock-offering","is_publish_highlight":false,"gpt_icon":0},{"id":"2432587379","title":"BRIEF-Soleno Therapeutics Announces Proposed Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2432587379","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432587379?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:03","pubTimestamp":1714680235,"startTime":"0","endTime":"0","summary":"May 2 (Reuters) - Soleno Therapeutics Inc   :   * SOLENO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCKSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432953197","title":"Soleno Therapeutics Announces Proposed Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2432953197","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432953197?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:01","pubTimestamp":1714651260,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., May  02, 2024  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.(Nasdaq:SLNO), (\"Soleno\" or the \"Company\"), a clinical-stage biopharmaceutical company developing novel therapeutics f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/02/2874655/0/en/Soleno-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431346334","title":"Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2431346334","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2431346334?lang=en_us&edition=fundamental","pubTime":"2024-04-30 12:00","pubTimestamp":1714449600,"startTime":"0","endTime":"0","summary":"Statistically Significant Improvements with DCCR Compared to Natural History of PWSfrom the PATH for PWS Study in Hyperphagia and PWS-related BehaviorsREDWOOD CITY, Calif., April  30, 2024  (GLOBE NEW","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/30/2872164/0/en/Soleno-Therapeutics-Announces-Peer-Reviewed-Publication-of-Data-Comparing-DCCR-Treatment-to-the-Natural-History-of-Prader-Willi-Syndrome.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431484296","title":"Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2431484296","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431484296?lang=en_us&edition=fundamental","pubTime":"2024-04-30 04:02","pubTimestamp":1714420936,"startTime":"0","endTime":"0","summary":"That's because it spoke with the FDA and the agency stated that if it was able to have a successful randomized withdrawal study,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4687282-soleno-mid-2024-nda-filing-for-pws-treatment-is-a-major-catalyst-to-watch","is_publish_highlight":false,"gpt_icon":0},{"id":"2431189061","title":"FLGC, BTOG and CAUD among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431189061","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431189061?lang=en_us&edition=fundamental","pubTime":"2024-04-30 00:31","pubTimestamp":1714408290,"startTime":"0","endTime":"0","summary":"Gainers: Collective Audience  +93%. Deciphera Pharmaceuticals  +72%. HWH International  +40%. Mullen Automotive  +32%. SEP Acquisition Corp  +30%. Bit Origin Ltd  +30%. SINTX Technologies  +32%. Koninklijke Philips N.V.  +28%. Phibro Animal Health Corp.  +27%.  Soleno Therapeutics  +25%.  Losers: Clever Leaves Holdings  -61%. Annovis Bio  -56%. Addex Therapeutics Ltd  -48%. mF International Ltd  -32%. Avenue Therapeutics  -23%. Intelligent Group Ltd  -19%. Nature Wood Group Ltd  -19%. Flora Growth Corp  -18%. China Jo-Jo Drugstores  -17%. Fitell Corp  -17%.","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095678-flgc-btog-and-caud-among-mid-day-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2431860585","title":"Soleno Therapeutics Shares Rise 37% After Breakthrough Designation for Diazoxide Choline","url":"https://stock-news.laohu8.com/highlight/detail?id=2431860585","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2431860585?lang=en_us&edition=fundamental","pubTime":"2024-04-29 22:45","pubTimestamp":1714401900,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics were trading near a three-year high after the Food and Drug Administration granted breakthrough therapy designation for diazoxide choline extended-release tablets to treat people 4 years and older with genetically confirmed Prader-Willi syndrome who have hyperphagia.Shares were 37% higher at $52 a share in midmorning trading. It hit an intra-day high of $53.82 on Feb. 28.The biopharmaceutical company said the designation shows that diazoxide choline may demonstrate substantial improvement on clinically significant endpoints over available therapies.Soleno expects to submit a New Drug Application for diazoxide choline in mid-2024.The FDA's breakthrough therapy designation aims to expedite the development and review of drugs intended to treat a serious condition.Diazoxide choline has an orphan drug designation for Prader-Willi syndrome in the U.S. and E.U., as well as a fast track designation in the U.S.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2431786468","title":"ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431786468","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431786468?lang=en_us&edition=fundamental","pubTime":"2024-04-29 22:02","pubTimestamp":1714399374,"startTime":"0","endTime":"0","summary":"Gainers: Deciphera Pharmaceuticals  +72%. Koninklijke Philips N.V. ADR  +35%. ImmunityBio  +38%. Soleno Therapeutics  +31%. ZyVersa Therapeutics  +23%.  Losers: Clever Leaves Holdings  -59%. Addex Therapeutics Ltd ADR  -50%. China Jo-Jo Drugstores  -20%. Avenue Therapeutics  -22%.  Aquestive Therapeutics  -17%.  S&P 500 Health Care Sector +0.52% to 1639.33. Health Care Equipment & Services +0.39% to 1936.74. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.67% to 1326.27.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095502-immunitybio-aquestive-therapeutics-clever-leaves-holdings-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2431848851","title":"Soleno Therapeutics receives breakthrough therapy designation from FDA for PWS treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2431848851","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431848851?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:29","pubTimestamp":1714393790,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics  announced that the FDA has granted Breakthrough Therapy Designation to diazoxide choline for the treatment of adults and children ages 4 years and older with genetically confirmed Prader-Willi syndrome who have hyperphagia. Diazoxide choline has Orphan Drug Designation for PWS in the U.S. and E.U., as well as Fast Track Designation in the U.S. Source: Press Release","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095420-soleno-therapeutics-receives-breakthrough-therapy-designation-from-fda-for-pws-treatment","is_publish_highlight":false,"gpt_icon":0},{"id":"2431985512","title":"Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2431985512","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2431985512?lang=en_us&edition=fundamental","pubTime":"2024-04-29 12:00","pubTimestamp":1714363200,"startTime":"0","endTime":"0","summary":"First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCRRemains","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/29/2871167/0/en/Soleno-Therapeutics-Receives-Breakthrough-Therapy-Designation-from-U-S-FDA-for-DCCR-Diazoxide-Choline-Extended-Release-Tablets-in-Prader-Willi-Syndrome-PWS.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429909409","title":"Soleno Therapeutics Board Member to Step Down Peacefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2429909409","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2429909409?lang=en_us&edition=fundamental","pubTime":"2024-04-23 04:33","pubTimestamp":1713817993,"startTime":"0","endTime":"0","summary":"An announcement from Soleno Therapeutics Inc (SLNO) is now available. Gwen Melincoff, a board member of Soleno Therapeutics, Inc., has decided not ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/soleno-therapeutics-board-member-to-step-down-peacefully?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/soleno-therapeutics-board-member-to-step-down-peacefully?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2428968386","title":"Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2428968386","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2428968386?lang=en_us&edition=fundamental","pubTime":"2024-04-20 04:05","pubTimestamp":1713557100,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23090597","is_publish_highlight":false,"gpt_icon":0},{"id":"2425686507","title":"Trade Alert: President Of Soleno Therapeutics Anish Bhatnagar Has Sold Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2425686507","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2425686507?lang=en_us&edition=fundamental","pubTime":"2024-04-06 20:28","pubTimestamp":1712406535,"startTime":"0","endTime":"0","summary":"Some Soleno Therapeutics, Inc. ( NASDAQ:SLNO ) shareholders may be a little concerned to see that the President, Anish...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/trade-alert-president-of-soleno-therapeutics-anish-bhatnagar","is_publish_highlight":false,"gpt_icon":0},{"id":"2424358691","title":"CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2424358691","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2424358691?lang=en_us&edition=fundamental","pubTime":"2024-04-04 13:54","pubTimestamp":1712210061,"startTime":"0","endTime":"0","summary":"GuruFocus has detected 2 Warning Sign with SLNO.This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.This article first appeared on","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VJpLp85HQVifQRn8zv.8Cg--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/35aeec5791dac62c9a3e33f8fdcc0433","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VJpLp85HQVifQRn8zv.8Cg--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/35aeec5791dac62c9a3e33f8fdcc0433"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ceo-bhatnagar-anish-sells-18-055421217.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421899264","title":"Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2421899264","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2421899264?lang=en_us&edition=fundamental","pubTime":"2024-03-22 19:20","pubTimestamp":1711106420,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insulet (PODD – Research Report), Biomea Fusion (BME...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insulet-podd-biomea-fusion-bmea-and-soleno-therapeutics-slno?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insulet-podd-biomea-fusion-bmea-and-soleno-therapeutics-slno?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2420212034","title":"Analysts’ Top Healthcare Picks: Soleno Therapeutics (SLNO), Optinose (OPTN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2420212034","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2420212034?lang=en_us&edition=fundamental","pubTime":"2024-03-18 19:00","pubTimestamp":1710759626,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics (SLNO – Research Report) and Opt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-soleno-therapeutics-slno-optinose-optn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-soleno-therapeutics-slno-optinose-optn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.soleno.life","stockEarnings":[{"period":"1week","weight":0.1908},{"period":"1month","weight":0.0805},{"period":"3month","weight":-0.0347},{"period":"6month","weight":0.9465},{"period":"1year","weight":10.599},{"period":"ytd","weight":0.121}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.036312},{"month":2,"riseRate":0.3,"avgChangeRate":0.282888},{"month":3,"riseRate":0.6,"avgChangeRate":-0.03782},{"month":4,"riseRate":0.4,"avgChangeRate":0.050488},{"month":5,"riseRate":0.7,"avgChangeRate":0.090361},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.099954},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.087265},{"month":8,"riseRate":0.555556,"avgChangeRate":0.004333},{"month":9,"riseRate":0.444444,"avgChangeRate":0.497463},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.150541},{"month":11,"riseRate":0.555556,"avgChangeRate":0.016977},{"month":12,"riseRate":0.4,"avgChangeRate":0.085183}],"exchange":"NASDAQ","name":"Soleno Therapeutics","nameEN":"Soleno Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Soleno Therapeutics,SLNO,Soleno Therapeutics股票,Soleno Therapeutics股票老虎,Soleno Therapeutics股票老虎国际,Soleno Therapeutics行情,Soleno Therapeutics股票行情,Soleno Therapeutics股价,Soleno Therapeutics股市,Soleno Therapeutics股票价格,Soleno Therapeutics股票交易,Soleno Therapeutics股票购买,Soleno Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction